Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alpine Immune Sciences Inc | ALPN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
64.62 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 6.71 - 64.70 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 64.62 | USD |
Alpine Immune Sciences (ALPN) Options Flow Summary
Alpine Immune Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.75B | 58.10M | - | 58.88M | -32.18M | -0.55 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alpine Immune Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALPN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 64.43 | 64.70 | 64.40 | 64.57 | 2,365,142 | 0.19 | 0.29% |
1 Month | 39.31 | 64.70 | 34.25 | 58.66 | 4,465,165 | 25.31 | 64.39% |
3 Months | 27.96 | 64.70 | 26.09 | 50.23 | 2,257,221 | 36.66 | 131.12% |
6 Months | 8.79 | 64.70 | 8.33 | 39.62 | 1,560,079 | 55.83 | 635.15% |
1 Year | 7.05 | 64.70 | 6.71 | 35.52 | 905,191 | 57.57 | 816.60% |
3 Years | 12.25 | 64.70 | 4.82 | 30.54 | 370,230 | 52.37 | 427.51% |
5 Years | 6.64 | 64.70 | 2.05 | 26.42 | 279,225 | 57.98 | 873.19% |
Alpine Immune Sciences Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202. |